Navigation Links
Chronic Lung Disease - Axentis Pharma Attracts Investment Interest
Date:2/2/2009

ded to join Axentis.

The increasing interest in Axentis and its lead product also resulted in a presentation at the Biotech Showcase 2009 in San Francisco by the company's CEO Dr. Helmut Brunar. Amongst the well over 225 companies present at the event, he had the privilege of presenting the company's success. "Our financial position is sufficiently strong that we decided to wait with a major round of financing until early 2010. Now is therefore the right time to present ourselves in the best light to powerful investors. Our lead product ARB-CF0223 - also known as Fluidosome(R) tobramycin - is expected to generate a peak annual turnover of approx. 100 million EUR within five years of market launch. The investment that we will be seeking in early 2010 will see us through until this entry onto the market. I consider Axentis an extremely attractive investment option. The feedback I received in San Francisco certainly confirmed this personal judgment."

The next opportunity to meet representatives of Axentis Pharma at European conferences will be at the BioSquare in Lyon, France, on March 9 to 11.

About Axentis Pharma AG (http://www.axentispharma.com)

Axentis Pharma AG is a Swiss company located in Zurich with a focus on developing therapeutic solutions for respiratory diseases, most prominently cystic fibrosis. Axentis' lead product is in phase II clinical trials. Market registration / approval is expected in 2012.

About Fluidosome(R) technology

Axentis Pharma's Fluidosome(R) technology uses biocompatible lipids endogenous to the lung that are formulated into small liposomes. This nanocapsule platform offers wide-ranging potential to cater to unmet medical needs such as cystic fibrosis and other respiratory diseases. In the case of Fluidosome(R) tobramycin, the interaction between tobramycin and the microbial c
'/>"/>

SOURCE Axentis Pharma AG
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Human Genome Sciences Announces Initiation of Phase 2b Trial of Albuferon(R) Dosed Monthly in Chronic Hepatitis C
2. Alfacells ONCONASE(R) and R-Amphinase Show Anti-Tumor Activity in Chronic Lymphocytic Leukemia and Acute Myeloblastic Leukemia Cells
3. Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C
4. ANA598 Receives Fast Track Designation From the FDA for the Treatment of Chronic Hepatitis C Infection
5. Pharos Innovations Joins Partnership to Fight Chronic Disease
6. Romark Announces Presentation of New Data for Nitazoxanide in Chronic Hepatitis C at AASLD 2008
7. UKs NICE Recommends Spinal Cord Stimulation for Patients with Chronic Neuropathic Pain
8. New Company to Develop Nutritional Interventions Against Chronic Inflammatory and Infectious Diseases
9. Physician to Implant the CATANIA(TM) Coronary Stent System With Polyzene(R)-F to Treat Chronic Total Occlusion During Live Case at the Paris Cardiovascular Interventions Course (Francophone) 2008
10. Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders
11. Angiotech receives CE Mark approval of HemoStream(TM) Chronic Dialysis Catheter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... August 22, 2014 Ophthalmic drug ... interesting and challenging endeavors as the anatomy, physiology ... properties to the foreign substances. Ocular drug delivery ... self medication and minimal use of needles; also ... drugs and provides specific targeting within the ocular ...
(Date:8/22/2014)... 2014 Research and Markets has ... Enzymes, Kits, & Reagents (Cloning, Epigenetics, PCR, Restriction Digestion, ... their offering. The global molecular biology ... and is expected to grow at a CAGR of ... enzymes, kits, & reagents find applications in a large ...
(Date:8/22/2014)... Toronto, Canada (PRWEB) August 22, 2014 ... traits in model organisms can be accelerated by ... design and manufacturing technologies, the custom SeqCap EZ ... such research. , Mr. Watson will additionally present ... seen with commercially available human and mouse exome ...
(Date:8/21/2014)... Hershey, PA & Rockville, MD (PRWEB) August 21, 2014 ... Inc. (ITI) is making progress in its development ... allergy to Japanese red cedar pollen. Phase IC studies ... to a real solution to hay fever. , The ... in over 35 million people in Japan. Mountain Cedar ...
Breaking Biology Technology:Ocular Drug Delivery Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Ocular Drug Delivery Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3Ocular Drug Delivery Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 4Global Molecular Biology Enzymes, Kits, & Reagents (Cloning, Epigenetics, PCR, Restriction Digestion, Sequencing) Market - Forecast to 2018 2Global Molecular Biology Enzymes, Kits, & Reagents (Cloning, Epigenetics, PCR, Restriction Digestion, Sequencing) Market - Forecast to 2018 3Efficient Identification of Protein-Coding Variants in a Model Organism Through Exome Sequencing, New Webinar Hosted by Xtalks 2Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 2Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 3Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 4
... Small Tree Communications , a supplier of high-performance networking ... software protocol called Blaze, expected to ship in the third ... High-Definition digital video editing. , ,Blaze will make it ... on the newer high-end 10 gigabit Ethernet cards. It ...
... Corporation and Middleton-based Bone Care International Inc. announced ... their proposed merger. , ,Genzyme and Bone Care have signed ... Care in an all-cash transaction valued at $33.00 per ... by Bone Care's shareholders at a meeting on ...
... - Stratatech Corp. was awarded a federal ... of General Medical Sciences to further develop its engineered human ... Madison and employs 18 people, according to the 2005 edition ... Its products are based on a source of pathogen-free human ...
Cached Biology Technology:Small Tree is streamlining digital video editing 2Small Tree is streamlining digital video editing 3
(Date:8/22/2014)... , August 22, 2014 ... ) has announced the addition of ... 2014-2018"  report to their offering.  ... ,Biometrics is a technology that helps ... on their physical or behavioral features. ...
(Date:8/22/2014)... Thomson Reuters , a leading source of ... at the University of California, Riverside in its 2014 ... of our times." , To generate the list, the ... identify researchers whose published work has had enormous impact. ... some 3,200 individuals who published the greatest number of ...
(Date:8/22/2014)... CA Research presented at the 29th Annual ... developed by Hera Therapeutics Inc. combats three types ... 70 percent of all cervical cancer. , When ... blocked the replication of HPV-16, HPV-18 and HPV-11 ... Thomas Broker, Ph.D., who presented the findings at ...
Breaking Biology News(10 mins):Biometrics Market in North America 2014-2018: Key Vendors are 3M Cogent, Cross Match, NEC and Safran SA 2Biometrics Market in North America 2014-2018: Key Vendors are 3M Cogent, Cross Match, NEC and Safran SA 35 UC Riverside scientists among world's most influential scientific minds 2
... from the devastating magnitude-7 earthquake that struck Haiti on ... that might have caused the quake, but installed four ... , University of Washington civil and environmental engineering professor ... to the United States Southern Command, responsible for all ...
... , Those who live in industrialized countries have easy access ... still common. That,s a problem because new research from Tel ... functioning of memory, may be even more critical than previously ... in adults. Begun at MIT, the research started as ...
... behavior of teenagers is well documented, University of ... finally unraveling the actual brain activity that can ... self-destructive behavior. Published in the current edition of ... brains are more sensitive to internal and environmental ...
Cached Biology News:Earthquake engineers release report on damage in Haiti 2Earthquake engineers release report on damage in Haiti 3Remember magnesium if you want to remember 2Pitt researchers report internal and environmental factors trigger unique brain activity in teens 2Pitt researchers report internal and environmental factors trigger unique brain activity in teens 3
For the development of an immunoprecipitation assay to measure Chk1 kinase activity in cell lysates....
Non-Protein Peroxidase Stabilizer , 1 L...
... is an agarose-digesting enzyme isolated from ... carbohydrate bonds in agarose producing carbohydrate ... The remaining carbohydrate molecules will not ... isolated with Gelzyme enzyme can be ...
RABBIT ANTI QUINOLINIC ACID...
Biology Products: